Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam and alfentanil for non-intubated general anesthesia during endoscopic submucosal tumor resection
ChiCTR2500097824Phase 4Not yet recruiting
- Sponsor
- Macheng People's Hospital
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remimazolam, alfentanil, propofol and sufentanil in gastrointestinal stromal tumor (GIST) (4 arms), sponsored by Macheng People's Hospital. Primary endpoint: Incidence of anesthesia-related adverse reactions. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
remimazolamalfentanilpropofolsufentanil
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR2500097824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097824.